Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies
- 1 May 2021
- journal article
- letter
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21 (5) , e483-e487
Abstract
No abstract availableFunding Information
- AbbVie
- National Institutes of Health (P30 CA016359)
- Takeda Pharmaceuticals U.S.A.
- National Cancer Institute
- Frederick A. DeLuca Foundation
- Boehringer Ingelheim
- Celgene
- Pfizer
This publication has 15 references indexed in Scilit:
- Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic TransplantationTransplantation and Cellular Therapy, 2019
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Fundamental Mechanisms of Immune Checkpoint Blockade TherapyCancer Discovery, 2018
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and LimitationsFrontiers in Oncology, 2018
- The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulationCell Communication and Signaling, 2017
- Ipilimumab for Patients with Relapse after Allogeneic TransplantationNew England Journal of Medicine, 2016
- Immune evasion in cancer: Mechanistic basis and therapeutic strategiesSeminars in Cancer Biology, 2015
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisBMC Medicine, 2015
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous RetrovirusesCell, 2015
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic MalignanciesClinical Cancer Research, 2008